News

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.

Stock performance snapshot Vertex Pharmaceuticals (VRTX) is drawing investor attention after recent trading left the stock around US$446.83, with returns mixed across different periods and a longer term track record that stands in contrast to more recent moves. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been choppy, with a 1-day share price return of 1.15% and a 30-day share price return of 4.49%, while the 1-year total shareholder return has slipped 0.81% and the...

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The market is underestimating these companies' long-term prospects.

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

If you are wondering whether Vertex Pharmaceuticals at around US$438 per share is priced attractively or already reflects its strengths, you are not alone. The stock has inched up 0.9% over the past week and 3.4% over the past month, while year to date it is down 3.0% and the 1 year return is also down 1.6%. This is set against a 31.1% gain over 3 years and a 109.6% gain over 5 years. These moves sit against a backdrop of ongoing interest in Vertex's pipeline and its position in treatments...

Vertex Pharmaceuticals recently reported that the FDA accepted its Biologics License Application for povetacicept in adults with immunoglobulin A nephropathy, with a PDUFA action date set for November 30, 2026, supported by Phase 3 data showing clinically meaningful reductions in proteinuria. This milestone marks a potential first commercial product in Vertex’s nephrology franchise, signaling progress in diversifying beyond its cystic fibrosis core. Next, we’ll explore how the FDA’s...

Vertex Pharmaceuticals (NASDAQ:VRTX) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free cash, while Wall Street prices it closer to a generic large-cap biotech than to the cash-flow compounder its financials describe. For a retirement-focused investor who has been burned chasing momentum, this is ... Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing

VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 4.1% return has trailed the S&P 500 by 6.2 percentage points.

Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the 12 Most Profitable Stocks to Invest In. On May 21, 2026, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that Health Canada accepted for review a New Drug Submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Vertex said suzetrigine is a selective NaV1.8 pain signal inhibitor and represents […]

Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.

If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech ... These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.

Vertex Pharmaceuticals has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

Vertex Pharmaceuticals (VRTX) stock has moved lower recently, with the price down about 2% over the past month and roughly 8% over the past 3 months, prompting closer attention from investors. See our latest analysis for Vertex Pharmaceuticals. Zooming out, Vertex’s recent share price weakness, including a 1-day share price return of down 0.89% and a 7-day share price return of down 4.99%, sits against a 5-year total shareholder return of 108.14%. This points to fading short term momentum...

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management highlighting commercial momentum in both established and emerging product areas. CEO Reshma Kewalramani pointed to "strong revenue growth as we reach more patients with more products," emphasizing milestone achievements for AlifTrack, KASJEVY, and Gernavix. The company also attributed performance to broader label eligibility and successful int

Halozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensu

Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed Germany's first sustainable access deal for CASGEVY, a gene therapy for severe sickle cell disease and transfusion dependent beta thalassemia. The agreement with GKV-Spitzenverband aims to secure long term, reimbursed access to this one time treatment for eligible patients across the German statutory health system. This adds to Vertex's broader reimbursement progress for CASGEVY in multiple countries, expanding global reach beyond its...

Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duchenne muscular dystrophy, or DMD, who have mutations amenable to exon 44 skipping

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.